Literature DB >> 20305130

Contralateral second breast cancers: prediction and prevention.

David J Brenner.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20305130     DOI: 10.1093/jnci/djq058

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  6 in total

1.  Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI.

Authors:  Jeon-Hor Chen; Hon Yu; Muqing Lin; Rita S Mehta; Min-Ying Su
Journal:  Magn Reson Imaging       Date:  2013-08-29       Impact factor: 2.546

2.  Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer.

Authors:  Genevieve M Monsees; Kathleen E Malone; Mei-Tzu C Tang; Polly A Newcomb; Christopher I Li
Journal:  J Natl Cancer Inst       Date:  2011-10-21       Impact factor: 13.506

3.  Effect of taxane-based neoadjuvant chemotherapy on fibroglandular tissue volume and percent breast density in the contralateral normal breast evaluated by 3T MR.

Authors:  Jeon-Hor Chen; Wei-Fan Pan; Julian Kao; Jocelyn Lu; Li-Kuang Chen; Chih-Chen Kuo; Chih-Kai Chang; Wen-Pin Chen; Christine E McLaren; Shadfar Bahri; Rita S Mehta; Min-Ying Su
Journal:  NMR Biomed       Date:  2013-08-12       Impact factor: 4.044

4.  On the Use of Optically Stimulated Luminescent Dosimeter for Surface Dose Measurement during Radiotherapy.

Authors:  Fasihah Hanum Yusof; Ngie Min Ung; Jeannie Hsiu Ding Wong; Wei Loong Jong; Vannyat Ath; Vincent Chee Ee Phua; Siew Ping Heng; Kwan Hoong Ng
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

Review 5.  Is there a role for IGF-1 in the development of second primary cancers?

Authors:  Thurkaa Shanmugalingam; Cecilia Bosco; Anne J Ridley; Mieke Van Hemelrijck
Journal:  Cancer Med       Date:  2016-10-13       Impact factor: 4.452

6.  Prediction and clinical utility of a contralateral breast cancer risk model.

Authors:  Daniele Giardiello; Ewout W Steyerberg; Michael Hauptmann; Muriel A Adank; Delal Akdeniz; Carl Blomqvist; Stig E Bojesen; Manjeet K Bolla; Mariël Brinkhuis; Jenny Chang-Claude; Kamila Czene; Peter Devilee; Alison M Dunning; Douglas F Easton; Diana M Eccles; Peter A Fasching; Jonine Figueroa; Henrik Flyger; Montserrat García-Closas; Lothar Haeberle; Christopher A Haiman; Per Hall; Ute Hamann; John L Hopper; Agnes Jager; Anna Jakubowska; Audrey Jung; Renske Keeman; Iris Kramer; Diether Lambrechts; Loic Le Marchand; Annika Lindblom; Jan Lubiński; Mehdi Manoochehri; Luigi Mariani; Heli Nevanlinna; Hester S A Oldenburg; Saskia Pelders; Paul D P Pharoah; Mitul Shah; Sabine Siesling; Vincent T H B M Smit; Melissa C Southey; William J Tapper; Rob A E M Tollenaar; Alexandra J van den Broek; Carolien H M van Deurzen; Flora E van Leeuwen; Chantal van Ongeval; Laura J Van't Veer; Qin Wang; Camilla Wendt; Pieter J Westenend; Maartje J Hooning; Marjanka K Schmidt
Journal:  Breast Cancer Res       Date:  2019-12-17       Impact factor: 6.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.